Cargando…
Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis
The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in ent...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598654/ https://www.ncbi.nlm.nih.gov/pubmed/36289648 http://dx.doi.org/10.3390/biomedicines10102387 |
_version_ | 1784816395705384960 |
---|---|
author | Gurke, Robert Bendes, Annika Bowes, John Koehm, Michaela Twyman, Richard M. Barton, Anne Elewaut, Dirk Goodyear, Carl Hahnefeld, Lisa Hillenbrand, Rainer Hunter, Ewan Ibberson, Mark Ioannidis, Vassilios Kugler, Sabine Lories, Rik J. Resch, Eduard Rüping, Stefan Scholich, Klaus Schwenk, Jochen M. Waddington, James C. Whitfield, Phil Geisslinger, Gerd FitzGerald, Oliver Behrens, Frank Pennington, Stephen R. |
author_facet | Gurke, Robert Bendes, Annika Bowes, John Koehm, Michaela Twyman, Richard M. Barton, Anne Elewaut, Dirk Goodyear, Carl Hahnefeld, Lisa Hillenbrand, Rainer Hunter, Ewan Ibberson, Mark Ioannidis, Vassilios Kugler, Sabine Lories, Rik J. Resch, Eduard Rüping, Stefan Scholich, Klaus Schwenk, Jochen M. Waddington, James C. Whitfield, Phil Geisslinger, Gerd FitzGerald, Oliver Behrens, Frank Pennington, Stephen R. |
author_sort | Gurke, Robert |
collection | PubMed |
description | The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in entheseal and synovial musculoskeletal structures, but a definitive diagnosis often can only be made by clinical experts or when an extensive progressive disease state is apparent. As with other IMIDs, the detection of multimodal molecular biomarkers offers some hope for the early diagnosis of PsA and the initiation of effective management and treatment strategies. However, specific biomarkers are not yet available for PsA. The assessment of new markers by genomic and epigenomic profiling, or the analysis of blood and synovial fluid/tissue samples using proteomics, metabolomics and lipidomics, provides hope that complex molecular biomarker profiles could be developed to diagnose PsA. Importantly, the integration of these markers with high-throughput histology, imaging and standardized clinical assessment data provides an important opportunity to develop molecular profiles that could improve the diagnosis of PsA, predict its occurrence in cohorts of individuals with psoriasis, differentiate PsA from other IMIDs, and improve therapeutic responses. In this review, we consider the technologies that are currently deployed in the EU IMI2 project HIPPOCRATES to define biomarker profiles specific for PsA and discuss the advantages of combining multi-omics data to improve the outcome of PsA patients. |
format | Online Article Text |
id | pubmed-9598654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95986542022-10-27 Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis Gurke, Robert Bendes, Annika Bowes, John Koehm, Michaela Twyman, Richard M. Barton, Anne Elewaut, Dirk Goodyear, Carl Hahnefeld, Lisa Hillenbrand, Rainer Hunter, Ewan Ibberson, Mark Ioannidis, Vassilios Kugler, Sabine Lories, Rik J. Resch, Eduard Rüping, Stefan Scholich, Klaus Schwenk, Jochen M. Waddington, James C. Whitfield, Phil Geisslinger, Gerd FitzGerald, Oliver Behrens, Frank Pennington, Stephen R. Biomedicines Review The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in entheseal and synovial musculoskeletal structures, but a definitive diagnosis often can only be made by clinical experts or when an extensive progressive disease state is apparent. As with other IMIDs, the detection of multimodal molecular biomarkers offers some hope for the early diagnosis of PsA and the initiation of effective management and treatment strategies. However, specific biomarkers are not yet available for PsA. The assessment of new markers by genomic and epigenomic profiling, or the analysis of blood and synovial fluid/tissue samples using proteomics, metabolomics and lipidomics, provides hope that complex molecular biomarker profiles could be developed to diagnose PsA. Importantly, the integration of these markers with high-throughput histology, imaging and standardized clinical assessment data provides an important opportunity to develop molecular profiles that could improve the diagnosis of PsA, predict its occurrence in cohorts of individuals with psoriasis, differentiate PsA from other IMIDs, and improve therapeutic responses. In this review, we consider the technologies that are currently deployed in the EU IMI2 project HIPPOCRATES to define biomarker profiles specific for PsA and discuss the advantages of combining multi-omics data to improve the outcome of PsA patients. MDPI 2022-09-24 /pmc/articles/PMC9598654/ /pubmed/36289648 http://dx.doi.org/10.3390/biomedicines10102387 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gurke, Robert Bendes, Annika Bowes, John Koehm, Michaela Twyman, Richard M. Barton, Anne Elewaut, Dirk Goodyear, Carl Hahnefeld, Lisa Hillenbrand, Rainer Hunter, Ewan Ibberson, Mark Ioannidis, Vassilios Kugler, Sabine Lories, Rik J. Resch, Eduard Rüping, Stefan Scholich, Klaus Schwenk, Jochen M. Waddington, James C. Whitfield, Phil Geisslinger, Gerd FitzGerald, Oliver Behrens, Frank Pennington, Stephen R. Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis |
title | Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis |
title_full | Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis |
title_fullStr | Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis |
title_full_unstemmed | Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis |
title_short | Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis |
title_sort | omics and multi-omics analysis for the early identification and improved outcome of patients with psoriatic arthritis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598654/ https://www.ncbi.nlm.nih.gov/pubmed/36289648 http://dx.doi.org/10.3390/biomedicines10102387 |
work_keys_str_mv | AT gurkerobert omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT bendesannika omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT bowesjohn omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT koehmmichaela omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT twymanrichardm omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT bartonanne omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT elewautdirk omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT goodyearcarl omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT hahnefeldlisa omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT hillenbrandrainer omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT hunterewan omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT ibbersonmark omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT ioannidisvassilios omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT kuglersabine omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT loriesrikj omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT rescheduard omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT rupingstefan omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT scholichklaus omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT schwenkjochenm omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT waddingtonjamesc omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT whitfieldphil omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT geisslingergerd omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT fitzgeraldoliver omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT behrensfrank omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT penningtonstephenr omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis |